Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Thyroxine for Transient Hypothyroxinemia in Preterm Newborns
NCT01306227Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2006
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levothyroxine sodium in transient hypothyroxinemia of prematurity (THOP) (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Neurodevelopmental outcome assessed by the Brunet-Lézine score at 2 years. Started Sep 2006; status: completed.
02
Drugs
levothyroxine sodium
03
Conditions
transient hypothyroxinemia of prematurity (THOP)
Beyond the preview
Go deeper on NCT01306227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306227.